Deal Watch: Allergan And Valeant Sign Deals, But Not With Each Other; All Eyes On Pfizer
Executive Summary
Allergan finds a white knight in Actavis and Valeant finds a plan B in diagnostics firm Nicox. Meanwhile Pfizer pays $850 million up front to license Merck KGAA’s anti-PD-L1 antibody, in the hopes of catching up in the immuno-oncology space, and BioMarin takes on Prosensa and its Duchenne muscular dystrophy candidate after it was abandoned by GSK.